Selexipag

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Selexipag
   1. Pharmacist Assessment Report
   2. Selexipag: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Selexipag: Known uses and market status in Canada

Summary

The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Selexipag, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are its own recorded uses, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	2
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 8 of 8)
Number of DINs	8 (marketed: 8)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
pulmonary hypertension	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
pulmonary arterial hypertension

Canada Market Information

Licence	Product	Dosage form	Status
02451174	UPTRAVI		Valid
02451220	UPTRAVI		Valid
02451182	UPTRAVI		Valid
02451158	UPTRAVI		Valid
02451204	UPTRAVI		Valid
02451212	UPTRAVI		Valid
02451190	UPTRAVI		Valid
02451166	UPTRAVI		Valid

Safety Considerations

• Drug Interactions: The interaction screening returned 100 records. The ones listed here are all rated Moderate. They include:
  • SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)
  • Vasoactive or sympathomimetic agents (epinephrine, ephedrine, phenylephrine, phentolamine)
  • Nitrite and nitrate-type agents (amyl nitrite, nitrous acid)
  • Papaverine, diazoxide, mannitol, glycerin
  • Amifostine, deferasirox, abiraterone, acebutolol

Please refer to the package insert for warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---